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Harsharan K. Singh,1 Howard Reisner,1 Vimal K. Derebail,2 Tomasz Kozlowski,3 and Volker Nickeleit1Background. A qualitative highly predictive urinary test for polyomavirus nephropathy (PVN) is the PV-Haufen test. This article
evaluates whether a quantitative PV-Haufen analysis, that is, the number of PV-Haufen shed per milliliter urine, predicts PVN dis-
ease grades and the severity of intrarenal PV replication.Methods.Polyomavirus-Haufenwere counted in 40 urine samples from
patients with biopsy-proven definitive PVN. The number of PV-Haufenwas correlatedwith both histologic PVN disease grades 1 to
3 and the number of SV40-T–expressing cells as indicators of intrarenal PV replication in corresponding renal allograft biopsies
(manual counts and automated morphometry). Findings from quantitative PV-Haufen analyses were compared to conventional
laboratory test results, that is, BK viremia (quantitative polymerase chain reaction [PCR]) and BK viruria (quantitative PCR and de-
coy cell counts). Results. Polyomavirus-Haufen counts showed excellent correlation (α0.77–0.86) with the severity of intrarenal
PV replication and disease grades. In particular, low PV-Haufen numbers strongly correlated with early PVN grade 1 and minimal
intrarenal expression of SV40-T antigen (P < 0.001). In comparison, BK viremia and viruria levels by PCR showed only modest
correlations with histologic SV40-T expression (α0.40–0.49) and no significant correlation with disease grades or minimal intra-
renal PV replication. No correlations were seen with urinary decoy cell counts. In contrast to conventional quantitative PCR assays
or decoy cell counts, quantitative urinary PV-Haufen testing accurately reflects the severity of PV replication, tissue injury, and PVN
disease grades. Conclusions. Quantitative PV-Haufen testing is a novel noninvasive approach to patient management for the
diagnosis and prediction of PVN disease grades and monitoring of disease course during therapy.
(Transplantation 2015;99: 609–615)Polyomavirus nephropathy (PVN) is the most impor-tant viral infection in renal allografts. The incidence of
PVN in kidney transplant recipients ranges from 4% to
12%.1‐4 ABO-incompatible grafts seem to be at increased
risk with a prevalence of 18%.5 Graft failure because of
PVN occurs in approximately 20% to 30% with a higher
prevalence of 50% in cases of sclerosed PVN disease grade
3 (data collected by the Banff working group on polyomavi-
rus nephropathy). Specific anti-PV therapy is not available,
and outcome largely depends on an early diagnosis of PVN
with limited renal injury that tends to respond favorablyReceived 22 April 2014.
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Transplantation ■ March 2015 ■ Volume 99 ■ Number 3to therapeutic intervention (mainly based on the reduction
of immunosuppression).
Polyomavirus nephropathy is defined morphologically by
the histologic demonstration of polyomavirus (PV) replica-
tion in the renal parenchyma, and a renal biopsy is required
to render a definitive diagnosis.6‐9 However, establishing a
diagnosis of PVN in a kidney biopsy can be challenging. De-
terioration of allograft function and a rise in serum creatinine
levels does not always accompany early PVN, resulting in a
possible delay of a diagnostic renal biopsy.6,8
Patient management after kidney transplantation includes
risk assessment for potential PVN with quantitative poly-
merase chain reaction (PCR) assays for BK virus loads in
plasma or urine or quantitation of urinary decoy cells in urine
cytology specimens. These assays have been the mainstays
for both clinical care and intervention.2,10‐19 They are basedSupplemental digital content (SDC) is available for this article. Direct URL citations
appear in the printed text, and links to the digital files are provided in the HTML
text of this article on the journal’s website (www.transplantjournal.com).
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signs of PV replication with viremia or viruria, and the as-
sumption that plasma PCR levels for BK virus reflect intra-
renal PV replication. However, only a minority of patients
with PV viremia or viruria ultimately develops PVN, under-
scoring a well-established fact: latency establishing DNA
viruses, such as PV, can be reactivated without causing man-
ifest disease.8,18,20‐24 Moreover, in immunocompromised
patients, BK virus–associated disease with viremia can also
be seen in the bladder (hemorrhagic cystitis) or in the sali-
vary glands (human immunodeficiency virus–associated sali-
vary gland sclerosis), typically lacking concurrent PVN.25‐28
Thus, positive PCR-based BK viremia or viruria test results
or the presence of decoy cells in the urine indicate viral acti-
vation and an increased risk for PVN, but the tests cannot
reliably predict the actual presence of intrarenal viral disease,
that is, definitive PVN. In the setting of PVN, an ideal bio-
marker would not only indicate the presence or absence of
intrarenal disease but also provide information on the sever-
ity of virally induced tissue injury.
We recently described a noninvasive biomarker to accu-
rately predict PVN in fixed voided urine samples, that is,
the PV-Haufen test. We showed that a qualitative analy-
sis, that is, PV-Haufen present or absent, marked intra-
renal disease with positive and negative predictive values
exceeding 95%.20,29 The PV-Haufen test is based on a
novel concept, that is, the detection of dense, cast-like PV
aggregates in fixed voided urine samples. Polyomavirus-
Haufen form in virally injured renal tubules subsequent
to PV release from infected tubular epithelial cells. They
are then flushed out of the diseased kidneys and can be
detected in the urine. In our previous publication, we re-
ported that PV-Haufen were exclusively found in patients
with biopsy-proven definitive PVN and were never seen in
139 control patients with varying degrees of BK viremia
and viruria and absence of PVN. In patients with a defini-
tive biopsy-proven diagnosis of PVN who were followed
longitudinally, PV-Haufen shedding went from negative to
positive at the time of initial biopsy diagnosis. Polyomavirus-
Haufen testing subsequently remained positive during per-
sistent viral nephropathy. At the time of disease resolution,
PV-Haufen testing turned from positive to negative and re-
mained negative thereafter during long-term follow-up. Thus,
the qualitative detection of urinary PV-Haufen, that is, pres-
ent or absent, is disease-specific and represents a novel clini-
cal biomarker for definitive PVN.20,30
Currently, it is undetermined whether a quantitative uri-
nary PV-Haufen analysis, that is, recording the number of
PV-Haufen shed per milliliter urine, could provide additional
clinical information on the severity of intrarenal disease. It
is also undetermined how a quantitative urinary PV-Haufen
assay might compare to conventional mainly PCR-based lab-
oratory screening tests for PVN.
We address these questions in our current study that ex-
pands on our previous qualitative PV-Haufen test findings
by now focusing on quantitative testing. Because PV-Haufen
shedding is only found in patients with biopsy-proven defini-
tive PVN, we hypothesize that the degree of urinary PV-
Haufen shedding reflects the severity of virally induced kidney
injury. The aim of our current study is to correlate traditional
screening assays and quantitative PV-Haufen test results
with the severity of intrarenal PV replication or PV burdenand disease grades in patients with biopsy-proven PVN.
Which test is most accurate?RESULTS
Correlation of Quantitative Screening Test Results
With the Severity of Intrarenal PV Replication
The severity of intrarenal PV replication was deter-
mined by using an immunohistochemical stain for the
SV40-Tantigen and manually counting the number of pos-
itive staining nuclei, the number of positive staining tubular
cross-sections, or alternatively performing (automated) mor-
phometry. Irrespective of manual or automated analysis, the
number of urinary PV-Haufen most accurately reflected
the severity of intrarenal PV replication–SV40-T expression
with excellent correlation coefficients between 0.77 and 0.86
(Table 1 and Figure 1). Of note, correlations were tightest
for comparisons based on the manual counts rather than
the (automated) morphometric deconvolution analyses using
the Aperio system. Plasma and urine PCR readings (BK vire-
mia and viruria) showed a modest correlation with intrarenal
PV replication (correlation coefficients between 0.40 and
0.49). No correlation was seen between the number of decoy
cells in the urine and the SV40-Texpression in the correspond-
ing biopsy samples.
For correlation studies of a subgroup of PVN cases with
minimal PV burden, six biopsies with 25 or less intrarenal
SV40-T antigen–expressing cells were selected. Five of these
six biopsies lacked intranuclear PV inclusion bodies by light
microscopy further supporting an early and limited PVN dis-
ease stage in these cases. All six cases showed low urinary PV-
Haufen numbers that tightly correlated with the low intrarenal
PV burden (σ = 0.91; P = 0.01). Lowest PV-Haufen counts
were found in one case with only two intrarenal SV40-T
antigen-expressing cells (Table 2). The PV-Haufen counts in-
creased in increments in the remaining five cases parallel to in-
creased intrarenal PV load levels. In contrast, in this cohort, no
significant correlations were found between all other screening
assays and minimal intrarenal PV replication: plasma PCR σ =
0.20, P = 0.7; urine PCR σ = −0.09, P = 0.9; and decoy cell
shedding σ = 0.02, P = 1.0.
Correlation of Screening Tests With PVN
Disease Grades
Low numbers of urinary PV-Haufen were statistically sig-
nificantly associated with early or mild PVN disease grade
1 in 12 of the 12 cases with a median PV-Haufen count of
282/mL urine and a maximum count of 677 PV-Haufen/mL
urine seen in one patient. Polyomavirus nephropathy disease
grade 2 showed median PV-Haufen counts significantly higher
at 1693/mL (range, 112–9977/mL urine; P =< 0.0001). On an
individual case basis, PV-Haufen counts showed only little
overlap between PVN disease grades 1 and 2 (Table 3 and
Figure 1S, A, SDC, http://links.lww.com/TP/B46). Polyoma-
virus nephropathy disease grade 3 demonstrated median
PV-Haufen counts of 2822/mL, which differed signifi-
cantly from PVN disease grade 1 (1 vs. 3 P = 0.002). In
comparison, the degree of BK viremia and BK viruria by
PCR testing and the degree of decoy cell shedding by urine
cytology were not significantly associated with PVN disease








































































































































































































































































































































































































































































































































© 2014 Wolters Kluwer Singh et al 611DISCUSSION
Urinary PV-Haufen are tight three-dimensional cast-like
viral aggregates that are easily detected in fixed urine samples
by negative staining electron microscopy (EM).20,29 In a pre-
vious study, we showed that the qualitative detection of PV-
Haufen, that is, present or absent, in a fixed urine specimen
predicted PVN with positive and negative predictive values
greater than 95%.20FIGURE 1. Correlation of quantitative screening test results with
intrarenal PV replication, that is, the number of SV40-T–expressing
tubular epithelial cells in a biopsy sample with PVN. A, Urinary PV-
Haufen; (B) Plasma PCR for BK virus; and (C) Urine PCR for BK virus.
Scatterplots with regression lines are depicted. PVN, polyomavirus
nephropathy; PCR, polymerase chain reaction.
TABLE 2.























PVN and minimal PV
replication (n = 6)
Absent 2 2 169 3.18 × 106 100 4.64 × 103
Absent 7 3 225 3.25 × 107 50 1.10 × 103
Absent 10 4 225 1.53 × 109 100 1.63 × 104
Present 12 6 282 1.48 × 107 20 5.93 × 104
Absent 16 12 451 2.27 × 107 45 2.97 × 103
Absent 25 17 451 8.24 × 107 100 2.00 × 104
σ = 0.91 σ = −0.09 σ = 0.02 σ = 0.20
P = 0.01 P = 0.9 P = 1.0 P = 0.7
a Immunohistochemical stain for the SV-40 Large T antigen.
In PVN: selected biopsies with minimal polyomavirus replication/SV40 positivity in 25 tubular epithelial cells or less.
σ = Pearson correlation coefficient: 0.0 to 0.2—very weak to negligible correlation. 0.2 to 0.4—weak, low correlation. 0.4 to 0.7—moderate correlation. 0.7 to 0.9—strong, high correlation.
PVN, polyomavirus nephropathy; PCR, polymerase chain reaction; BKV, BK virus.
612 Transplantation ■ March 2015 ■ Volume 99 ■ Number 3 www.transplantjournal.comIn the current study, we extended our analysis to quantita-
tive urinary PV-Haufen testing. We correlated the number
of PV-Haufen in voided urine samples with the severity of
PVN and compared the data to standard PV screening as-
says. This comprehensive comparative analysis showed that
quantitative urinary PV-Haufen testing most accurately re-
flected the severity of intrarenal PV replication and virally in-
duced renal injury. Few PV-Haufen in urine samples were
associated with limited intrarenal PV replication, including
one case with only two intrarenal SV40-T–expressing cells.
Counts increased in increments parallel to the increase of
intrarenal PV replication and high numbers of urinary PV-
Haufen reflected marked virally induced tubular injury, a
high intrarenal PV burden (correlation coefficient, 0.86).
Quantitative PV-Haufen testing also reflected PVNdisease
grades as proposed by the Banff Working Group on PVN.31
Early mild PVN disease grade 1 was reflected by low num-
bers of urinary PV-Haufen that differed significantly from
much higher counts in the florid PVN disease grade 2, and
the late and sclerosed PVN disease grade 3.
How can the striking correlation between the severity
of virally induced tissue injury in PVN and the numbers
of urinary PV-Haufen shed into the urine be explained?
The formation of PV-Haufen appears to be similar to theTABLE 3.
Quantitative screening test results by PVN disease grade
Screening tests for polyomavirus PVN grade 1 (n = 12) PVN g
PV-Haufen (#/mL urine) median, 282 m
range, 169–677 rang
Urine PCR (# copies/mL urine) median, 3.80 × 107 medi







median, 1.41 × 104 medi
range, 4.99 × 102 to 2.22 × 105 range, 2.50
a Wilcoxon rank-sum test for between group comparisons with Bonferroni correction (performed only if ov
b Not significant.
PVN, polyomavirus nephropathy; PCR, polymerase chain reaction; BKV, BK virus.formation of other intratubular casts such as red or white
blood cell casts. Polyomavirus-Haufen form within virally
injured renal tubules containing high concentrations of
uromodulin (Tamm-Horsfall protein) that has previously
been shown to facilitate aggregation of influenza, mumps,
and Newcastle viruses.32 High concentrations of Tamm-
Horsfall protein facilitate the aggregation of PV in vitro
(personal observation; manuscript in preparation).30 Because
PV-Haufen are flushed with the urine out of tubules and into
the bladder, they can serve as specific urinary biomarkers for
intrarenal PVN.
In contrast, quantitative PCR assays to detect BK virus in
plasma and urine only showed modest correlation with the
severity of intrarenal PV replication or PV burden (correla-
tion coefficients, 0.43 to 0.48). No significant correlations
were found between quantitative PCR test results and PVN
disease grades or limited PVN with only minimal intrarenal
disease. No significant correlations were seen with urinary
decoy cell counts. These results could be explained by poten-
tial PVactivation in sites other than the kidneys, such as the
urothelium or salivary glands.25‐28
In daily practice, we do not recommend using quantitative
urinary PV-Haufen testing as a mass screening tool. Rather,
it should be used as a targeted test to separate patientsrade 2 (n = 23) PVN grade 3 (n = 5) Pa
edian, 1,693 median, 2,822 0.0001
e, 112–9,977 range, 1,128–8,014 1 vs. 2 ≤ 0.0001
2 vs. 3 = 0.3b
1 vs. 3 = 0.001
an, 1.10 × 108 median, 3.20 × 108 0.09b
× 105 to 4.79 × 109 range, 7.24 × 107 to 1.57 × 1010
edian: 50 median, 100 0.3b
ge: 10–100 range, 50 × 100
an, 2.57 × 104 median, 1.52 × 105 0.1b
× 102 to 1.88 × 107 range, 3.50 × 103 to 6.18 × 106
erall group comparison by Kruskal-Wallis testing significant).
© 2014 Wolters Kluwer Singh et al 613with asymptomatic transient BK viral activation from those
with intrarenal disease, that is, definitive PVN. The test pro-
vides specific diagnostic evidence of intrarenal PVN and
gives prognostic information on the severity of virally in-
duced tissue injury. It is particularly suited for the diagno-
sis of PVN in early disease grade 1 with minimal intrarenal
disease. Quantitative urinary PV-Haufen testing could be
used tomonitor PVNprogression or regression during persis-
tent disease.
Urinary PV-Haufen testing is performed using negative
staining EM, a well-established, easily performed technique
specifically developed for the identification and quantitation
of viruses in various body fluids.33 It has been in routine
use in virology since the early 1960s and is the method of
choice for viral studies at major virology centers, such as
The Centers for Disease Control in Atlanta, GA. The incor-
poration of urinary PV-Haufen testing only requires “think-
ing outside the box.” The turnaround time from receipt of
a voided urine sample to reporting of results is approximately
3 hr with costs lower or comparable to PCR-based assays.
Although this single center study has limitations because
of relatively few cases analyzed, we nevertheless think that
quantitative urinary PV-Haufen testing will help to better
define, diagnose, and manage PVN.
In conclusion, urinary PV-Haufen are accurate biomarkers
of PVN and the number of PV-Haufen shed in fixed voided
urine samples accurately reflects the severity of intrarenal
disease. Quantitative PV-Haufen testing allows for an early
diagnosis of PVN and monitoring of changing intrarenal
viral load levels during therapeutic interventions such as in
the setting of new clinical drug trials.
MATERIALS AND METHODS
Based on the availability of concomitant blood, urine, and
renal biopsy samples, cases of definitive PVN were selected
from the archives of The University of North Carolina at
Chapel Hill (total n = 40 sample sets). The study protocol
was approved by the institutional review board. Per defini-
tion, all diagnostic renal allograft biopsies showed evidence
of PVN.6‐8 Histologic material was evaluated by two pathol-
ogists (V.N., H.K.S.) at a multiheaded scope and scoring
results based on consensus (including the count of SV40-T–
positive cells and tubules) were used for statistical analysis.
Urine samples collected on the day of biopsy were analyzed
by conventional urine cytology (ThinPrep; Hologic Incorpo-
rated, Bedford, MA) for decoy cells, negative staining EM
for the detection and quantitation of PV-Haufen, and quan-
titative PCR for BKV gene sequences. For negative staining
EM, urine was fixed in a 1:1 ratio of 4% paraformaldehyde
with subsequent EM grid preparation using previously pub-
lished methods. This protocol does not require any embed-
ding procedures and thin sectioning is not needed (SDC,
Materials and Methods, http://links.lww.com/TP/B46).20,29,33
Plasma samples collected on the day of biopsy were analyzed
by quantitative PCR for BKV gene sequences.
Biopsy Samples and Diagnosis of PVN
All renal allograft biopsies fulfilled the Banff ’97 criteria
for tissue adequacy and were evaluated according to standard
guidelines.34 The PVN classification into disease grades 1 to
3 followed proposals made by the 2013 BANFF working
group on the classification of Polyomavirus Nephropathy.31Polyomavirus nephropathy grades (1 = early/mild; 2 = florid;
3 = late/sclerosed) were defined based on the severity of PV
replication or degree of staining for the SV40-T antigen in
combination with the Banff “ci” interstitial fibrosis score.
Twelve of 40 cases were diagnosed as early or mild PVN
grade 1 (Figure 2S, A and D, SDC, http://links.lww.com/TP/B46),
23/40 as florid PVN grade 2 (Figure 2S, B and E, SDC,
http://links.lww.com/TP/B46) and 5 of 40 as late sclerosed PVN
grade 3 (Figure 2S, C and F, SDC, http://links.lww.com/TP/B46).
Quantitative Analysis of the SV40-T Antigen
Immunostain in Renal Biopsies
Intrarenal polyomavirus replication was assessed by immu-
nohistochemistry with a monoclonal mouse antibody directed
against the SV40-T antigen following previously published
protocols (Clone 416, Calbiochem, San Diego, CA) (Figure 2S,
D, E, and F, SDC, http://links.lww.com/TP/B46).35 Expression
levels of the SV40-T antigen, that is, the number of epithe-
lial cell nuclei expressing the T antigen, were quantitatively
analyzed by manual count and also by (automated) mor-
phometry using the Aperio system (Aperio, Vista, CA).
Manual Counts
(a) The total number of tubular epithelial cell nuclei ex-
pressing the SV40-T antigen and (b) the total number of
stained tubular cross-sections lined by one or more epithelial
cells expressing the SV-40 large T antigen were recorded.
Morphometric Analysis
The percentage area of a renal biopsy demonstrating pos-
itive expression with the SV40-T antigen was accomplished
as follows:
Aperio Color Deconvolution Software version 10.0 was
applied to 40× virtual images in “svs” format scanned on
the Aperio CS scanner (Aperio, Vista, CA). The total biopsy
area was determined using the total stained area of all cellular
components read using a channel optimized for blue nuclear
counterstain. To evaluate the % of SV40-T–positive staining
in the total biopsy area (TS1), the total immunopositive area
including both specific intranuclear staining and nonspecific
background staining was determined using the DAB channel
as specified by Aperio (% DAB). To calculate the specific
intranuclear SV-40 large T antigen signals, the weak positive
threshold (TSDAB) was set to eliminate presumed nonspecific
background staining as, for example, seen in the cytoplasm.
The final % of SV-40–positive staining (%IMMUNOPOSITIVE)
was calculated as: %IMMUNOPOSITIVE ¼ %DABð Þ  TSDABTS1
 
.
Negative Staining EM for the Detection and
Quantitation of PV Haufen
PV-Haufen Definition
“Haufen” (after a German word for “cluster” or “stack”)
were defined as discrete three-dimensional, cast-like, dense
polyomavirus aggregates in voided urine samples analyzed
by negative staining EM (Figure 2). Polyomavirus casts contain-
ing six or more polyomavirus virions were classified as “PV-
Haufen” following our previously published approach.20,29
Negative Staining EM and PV-Haufen Quantitation
Negative staining EM was performed using previously
published standard procedures with a two-step methodology
FIGURE 2. Negative staining electron microscopy depicting a char-
acteristic PV-Haufen in a voided urine sample. Haufen are tight three
dimensional viral casts composed of six or more individual PV virions.
Note the large size of this PV-Haufen and the diagnostic viral capsid
substructure and uniformity allowing easy identification by electron
microscopy (inset) (uranyl acetate stain: ×100,000 magnification).
PV, polyomavirus.
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terials and Methods, http://links.lww.com/TP/B46 and
Table 1S, SDC, http://links.lww.com/TP/B46).20,29,33 One
EM grid was prepared for each voided urine sample.
Haufen quantitation was performed according to estab-
lished previously published methodologies specifically de-
signed for the quantitation of viruses in body fluids.33,36
Briefly, PV-Haufen in the voided urine sample adhered to
the EM grid by electrostatic binding properties (Figure 3S,
SDC, http://links.lww.com/TP/B46). Electron microscopy
grids were examined on a transmission electron microscope
(LEO EM-910, LEO Electron Microscopy, Thornwood,
NY, accelerating voltage, 80–100 kV). A total of 25 ran-
domly selected grid fields were viewed at 50,000×magnifica-
tion and PV-Haufen were counted in these 25 grid fields at
80,000–100,000× magnification. The examination time
was, on average, 20 to 30 min per grid. The total number
of PV-Haufen per mL urine was then calculated using the
following formula:
Haufen=25 grid fields  whole grid area
area of 25 grid squares
 
 volume of total urine concentrate
volume of applied concentrate
= total starting urine volume
 
¼ number of Haufen=mL urine
(methodology used by the Centers for Disease Control per Dr.
Charles Humphrey, Chief, Infectious Disease Pathology).33,36
Quantitative PCR
Plasma and urine BK polyomavirus loads were determined
by a real-time quantitative PCR assay using the ABI PRISM
7900HT Sequence Detection System with well characterized
probes and primers specific for BK virus as previously pub-
lished.15,20 Real-time detection of PCR products was achieved
with a fluorescent hydrolysis (Taqman) probe. Primers andprobes were purchased from TIB Molbiol LLC, Adelphia,
NJ. Quantitative linearity of the assay extended from 10 to
109 measured copies of BKV equivalents correlating with a
dynamic linear range of 250 to 2.5 × 1010 BKV copies/mL
urine or plasma. Detectable BKV DNA below the lower limit
of linearity (<250 BKV copies/mL) was classified as a “low-
positive” result.
Urine Cytology for Decoy Cell Quantitation
All urine samples were processed for cytology using stan-
dard liquid-based procedures (Hologic Incorporated, Bedford,
MA) and stained by Papanicolaou method. Decoy cells were
identified and quantified as reported previously.11
Statistical Analysis
Statistical analyses were performed with standard pro-
grams (Microsoft Excel and Stata 12.1; Stata Corp, College
Station, TX). The number of urinary PV-Haufen, number
of decoy cells, urine and plasma BKV DNA load levels were
correlated with: (a) the severity of intrarenal PV replication/
SV40-T staining using Pearson’s correlation coefficient and
Spearman’s correlation coefficient and, (b) PVN disease
grades 1 to 3 using Wilcoxon rank-sum testing, and Kruskal-
Wallis testing with ties. Wilcoxon rank-sum testing for pair-
wise comparisons with Bonferroni correction was performed
only if overall group comparison by Kruskal-Wallis testing
was significant. All testing was performed with two-sided
α = 0.05.
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